DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Clinical trials for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT trials appear
Sign up with your email to follow new studies for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for deadly brain tumors: experimental combo targets DIPG
Disease control Recruiting nowThis study tests whether adding an experimental drug called VRT106 to standard radiation therapy can help control a rare, fast-growing brain tumor called diffuse midline glioma (including DIPG). About 10 adults aged 18 to 75 will receive the combination treatment. The main goal i…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE2 • Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 03:38 UTC
-
Experimental vaccine plus immunotherapy offers new hope for children with deadly brain tumors
Disease control Recruiting nowThis early-stage trial tests a new vaccine (rHSC-DIPGVax) combined with two immunotherapy drugs (BALSTILIMAB and ZALIFRELIMAB) in children with DIPG or diffuse midline glioma. The vaccine is designed to help the immune system recognize and attack tumor cells. The main goal is to …
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Disease control
Last updated May 26, 2026 03:37 UTC
-
Sound waves may help chemo reach deadly childhood brain tumors
Disease control Recruiting nowThis early-stage study tests whether focused ultrasound can safely open the blood-brain barrier in children with progressive diffuse midline glioma (DMG), a rare and aggressive brain tumor. The goal is to allow more of the chemotherapy drug etoposide to reach the tumor while redu…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: Columbia University • Aim: Disease control
Last updated May 26, 2026 03:33 UTC
-
New hope for kids with aggressive brain tumors: targeted drug combo after radiation
Disease control Recruiting nowThis study tests whether adding two different drug combinations after radiation can help children and young adults with high-grade gliomas (including DIPG) live longer. One group receives ribociclib plus everolimus, and another receives ribociclib plus temozolomide, based on the …
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated May 26, 2026 02:48 UTC
-
Could two weeks of radiation be as good as six for this brain cancer?
Symptom relief Recruiting nowThis study is for people with a rare, aggressive brain tumor called diffuse midline glioma. Instead of the usual 6 weeks of daily radiation, researchers are testing a 2-week course. The goal is to see if the shorter treatment works just as well and helps patients feel better duri…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated May 26, 2026 03:33 UTC
-
New brain tumor labels could change how doctors treat you
Knowledge-focused Recruiting nowThis study watches 1650 people with different types of brain tumors to see if the new 2021 classification system helps doctors choose better treatments. Researchers will track how long patients live and how well their tumors respond to therapy. The goal is to create clearer treat…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Knowledge-focused
Last updated May 26, 2026 03:28 UTC